100% autologous tissue regeneration platform

Our technology enables the production of a complete autologous engineered tissue composed of matrix and cells derived from patients’ own tissues. The scaffold is a thermo-responsive hydrogel, prepared by decellularization of patient’s omentum biopsy, while the induced pluripotent stem cells (iPSCs) are re-programmed from patient’s mature cells. Ex-vivo differentiation of iPSCs within the thermo-responsive hydrogel leads to the generation of a functional mature tissue.

Learn More
Small biopsy of patient's omentum
undergoes a proprietary
decellularization process.
Separating stromal cells and extracellular
matrix (ECM) from which iPSCs and
personalized hydrogel are produced.
The stem cells are differentiated within the gel to the desired tissue
The engineered tissue is re-implemented in the patient

The future of Spinal Cord Injury treatment

Our proprietary technology platform is the essence of engineering autologous neural implants. Differentiated iPSCs derived neural cells within extra cellular matrix (ECM) creates functional spinal cord implants that can bridge and regenerate injured spinal cord tissue. A first in human phase I/IIa clinical trial is scheduled for 2024.


“Imagine a day when your patient’s own cells are grown into any functional tissue implant.”

Asaf Toker – CEO

World’s first
3D-printed heart
using human cells

In 2019, Matricelf licensed the technology that enabled printing the first [functioning] 3D human heart from cells and matrix derived from a human omentum biopsy from Tel Aviv University.

Novel tissue
engineering technology
addressing multiple
clinical indications

Matricelf’s novel regenerative medicine platform aims to cure a range of medical conditions including Spinal Cord Injuries (SCI), Age-related Macular Degeneration (AMD), Parkinson’s Disease, Myocardial Infarction et al.

Making headlines in scientific publications

Awards and Recognition

Contact Us

Feel free to drop us a line below!